Fasting GLP-1 Levels in Women with PCOS and CAH

Polycystic ovarian syndrome (PCOS) is the most prevalent condition associated with increased androgens, but some rare diseases, e.g., congenital adrenal hyperplasia (CAH), should also be considered in the differential diagnosis of hyperandrogenemia. The potential role of incretin hormones has been t...

Full description

Bibliographic Details
Published in:	Acta Medica Bulgarica
Main Authors:	Robeva R., Kirilov G., Elenkova A., Zacharieva S.
Format:	Article
Language:	English
Published:	Sciendo 2024-12-01
Subjects:	cah pcos glp-1 hyperandrogenism incretin
Online Access:	https://doi.org/10.2478/amb-2024-0071

Similar Items

Evidence for Involvement of GIP and GLP-1 Receptors and the Gut-Gonadal Axis in Regulating Female Reproductive Function in Mice
by: Dawood Khan, et al.
Published: (2022-11-01)

Risk Factors for Hypertension in Polycystic Ovary Syndrome: Evidence from a Retrospective Study
by: Ralitsa Robeva, et al.
Published: (2025-09-01)

CYP21A2 Intron 2 Genetic Variants Might Be Associated with the Clinical Characteristics of Women with PCOS
by: Ralitsa Robeva, et al.
Published: (2024-07-01)

Hyperandrogenic Symptoms Are a Persistent Suffering in Midlife Women with PCOS; a Prospective Cohort Study in Sweden
by: Sofia Persson, et al.
Published: (2022-12-01)

Increased Serum AMH in a Subgroup of Women with Idiopathic Hyperandrogenism: Do These Women Have PCOS?
by: Enrico Carmina, et al.
Published: (2025-08-01)

Contribution of GIP and GLP-1 to the Insulin Response to Oral Administration of Glucose in Female Mice
by: Bo Ahrén
Published: (2023-02-01)

Unraveling PCOS: Exploring its causes and diagnostic challenges
by: Dar Mohd Altaf, et al.
Published: (2024-04-01)

First GLP-1 analog liraglutide: the result of clinical trails on efficacy
by: Alexander Sergeevich Ametov, et al.
Published: (2011-12-01)

PCOS as a generational disease - risks to mother and children
by: Karolina Gendek, et al.
Published: (2023-07-01)

Are GLP-1 Analogues a New Solution for the Treatment of NAFLD?
by: Maria Sudoł, et al.
Published: (2024-12-01)

Increased Prevalence of Elevated DHEAS in PCOS Women with Non-Classic (B or C) Phenotypes: A Retrospective Analysis in Patients Aged 20 to 29 Years
by: Enrico Carmina, et al.
Published: (2022-10-01)

Insulin resistance and insulin secretory defect among Bangalee PCOS women: a case-control study
by: Jannatul Nayeem, et al.
Published: (2024-09-01)

Specific loss of GIPR signaling in GABAergic neurons enhances GLP-1R agonist-induced body weight loss
by: Jordan Wean, et al.
Published: (2025-05-01)

Physiological and pharmacological actions of glucagon like peptide-1 (GLP-1) in domestic animals
by: Jorge F A Model, et al.
Published: (2022-06-01)

The Impact of the Ketogenic Diet on the Metabolic Profile, Hormonal Balance and Fertility in Women with PCOS
by: Mariola Turemka, et al.
Published: (2024-12-01)

GLP-1 Receptor Agonists’ Impact on Fertility - A Review
by: Joanna Wojda, et al.
Published: (2025-02-01)

GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes
by: Sydney S. Wilbon, et al.
Published: (2023-12-01)

Improving Reproductive Outcomes in PCOS: The Emerging Role of GLP-1 Receptor Agonists
by: Adrianna Tabeau, et al.
Published: (2025-03-01)

Effect of GIP and GLP-1 infusion on bone resorption in glucose intolerant, pancreatic insufficient cystic fibrosis
by: Wang Shin Lei, et al.
Published: (2025-06-01)

Increase in circulating GLP-1 following low FODMAP diet in irritable bowel syndrome patients
by: Umael Khan, et al.
Published: (2025-08-01)

Relations of Insulin Resistance, Body Weight, Vitamin D Deficiency, SHBG and Androgen Levels in PCOS Patients
by: Zsófi Balogh, et al.
Published: (2025-07-01)

The Sensory Mechanisms of Nutrient-Induced GLP-1 Secretion
by: Anna Pii Hjørne, et al.
Published: (2022-05-01)

Soy Isoflavones and PCOS: Role in Hormonal and Metabolic Mechanisms
by: Katarzyna Dereń, et al.
Published: (2025-05-01)

Secretion of glucagon, GLP-1 and GIP may be affected by circadian rhythm in healthy males
by: Dorte B. Zilstorff, et al.
Published: (2024-03-01)

The Lipid Profiles in Different Characteristics of Women with PCOS and the Interaction Between Dyslipidemia and Metabolic Disorder States: A Retrospective Study in Chinese Population
by: Fei Guo, et al.
Published: (2022-07-01)

The Origin and Understanding of the Incretin Concept
by: Jens F. Rehfeld
Published: (2018-07-01)

Case report: GLP1RA for the treatment of diabetes in liver transplanted people. Do they increase the risk of pancreatitis?
by: Valeria Grancini, et al.
Published: (2024-05-01)

CAH Newborn Screening in India: Challenges and Opportunities
by: Aashima Dabas, et al.
Published: (2020-08-01)

Declining muscle NAD+ in a hyperandrogenism PCOS mouse model: Possible role in metabolic dysregulation
by: Ali Aflatounian, et al.
Published: (2022-11-01)

Metanephrine and Normetanephrine Urine Excretion in Patients with PCOS
by: Robeva R., et al.
Published: (2022-06-01)

Effect of oral contraceptives and/or metformin on GLP-1 secretion and reactive hypoglycaemia in polycystic ovary syndrome
by: Dorte Glintborg, et al.
Published: (2017-06-01)

SRSFs mediate the function of AR in the ovarian granulosa cells of patients with PCOS
by: Jing Luo, et al.
Published: (2021-01-01)

Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
by: Tomislav Bulum
Published: (2022-10-01)

Molecular mapping and functional validation of GLP-1R cholesterol binding sites in pancreatic beta cells
by: Affiong Ika Oqua, et al.
Published: (2025-04-01)

Incretins role in Latent autoimmune diabetes of adults pathogenesis, the possibility of therapy with combination of glucagon-like peptide-1 agonist (GLP-1) and insulin.
by: Iuliia V. Silko, et al.
Published: (2016-07-01)

The interplay between PCOS pathology and diet on gut microbiota in a mouse model
by: Valentina Rodriguez Paris, et al.
Published: (2022-12-01)

Life Modifications and PCOS: Old Story But New Tales
by: Yuanyuan Gu, et al.
Published: (2022-04-01)

Polycystic Ovary Syndrome and NC-CAH: Distinct Characteristics and Common Findings. A Systematic Review
by: Georgios Papadakis, et al.
Published: (2019-06-01)

Dual GIP–GLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential
by: Bastin M, et al.
Published: (2019-09-01)

Effects of Congenital Adrenal Hyperplasia (CAH) and Biological Sex on Brain Size
by: Eileen Luders, et al.
Published: (2024-07-01)